A 52-year-old woman undergoes mastectomy for invasive ductal carcinoma of the breast. Histopathology reveals intermediate nuclear grade, moderate mitotic activity, and glandular differentiation. Which of the following is NOT a feature associated with improved prognosis in breast carcinoma?

## Prognostic Factors in Breast Carcinoma ### Overview of Favorable Prognostic Indicators **Key Point:** Prognostic factors in breast cancer include histological type, grade, stage, hormone receptor status, HER2 status, and molecular subtype. Understanding which features predict better vs. worse outcomes is essential for NEET PG. ### Molecular Subtypes and Prognosis | Subtype | ER/PR | HER2 | Ki-67 | Prognosis | 5-yr DFS | | --- | --- | --- | --- | --- | --- | | Luminal A | Positive | Negative | Low | Excellent | ~90% | | Luminal B | Positive | Variable | High | Good | ~80% | | HER2-enriched | Negative | Positive | High | Poor | ~65% | | Triple-negative | Negative | Negative | High | Poor | ~55% | **High-Yield:** Luminal A (ER+/PR+/HER2−/low Ki-67) has the BEST prognosis among all molecular subtypes. ### Why HER2 Amplification is a Poor Prognostic Sign 1. **HER2-positive tumors** (regardless of ER/PR status) are associated with: - Aggressive biological behavior - Higher proliferation rates (high Ki-67) - Increased propensity for visceral metastases - Worse overall survival without targeted therapy (trastuzumab) 2. **Clinical Pearl:** HER2 positivity is a **negative prognostic factor** in untreated disease, though it becomes a **predictive factor** for response to HER2-targeted agents (trastuzumab, pertuzumab). ### Favorable Histological Types **Mnemonic: TMIC** — Tubular, Mucinous, Inflammatory (rare), Medullary - **Tubular carcinoma:** 5-year survival ~95% - **Mucinous carcinoma:** 5-year survival ~90% - Both have low-grade nuclei and excellent prognosis ### Lymphocytic Infiltration **Key Point:** Tumor-infiltrating lymphocytes (TILs) at the tumor margin indicate an active immune response and are associated with: - Better response to therapy - Improved disease-free survival - Favorable prognosis, especially in triple-negative cancers ### Summary Table: Prognostic Features | Feature | Prognosis | Notes | | --- | --- | --- | | Luminal A subtype + low Ki-67 | **Excellent** | Best overall | | TILs at margins | **Favorable** | Active immunity | | HER2 amplification | **Poor** | Aggressive behavior | | Tubular/mucinous type | **Excellent** | Low-grade, indolent | | Triple-negative | **Poor** | Limited targeted options | **Warning:** Do not confuse HER2 as a prognostic factor (it is negative) with its role as a **predictive factor** for trastuzumab response (positive). ## Answer Justification **High expression of HER2 with gene amplification** is the ONLY feature that is **NOT associated with improved prognosis**. In fact, it is a **poor prognostic factor** and indicates aggressive disease with higher risk of recurrence and metastasis.